Abstracts tagged "Inflammation"

Abstract Number: 0489 • ACR Convergence 2025
Efficacy and safety profile of JAK inhibitors in current practice in rheumatoid arthritis
Omar Al Tabaa¹, Salomé Abdellaoui¹, Sophie Hecquet¹, Marion Thomas², Sandrine Carves¹, Alice Combier¹, Olivier Fogel³, Yannick Allanore⁴ and Jérôme Avouac⁵, ¹Rheumatology department, Cochin Hospital, Paris, France, ²APHP, Paris, France, ³AP-HP, Paris, France, ⁴Université Paris Cité, Paris, France, ⁵Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: JAKi have been used in rheumatoid arthritis in current practice for several years now, with the progressive arrival on the market of 4 molecules.…
Abstract Number: 0233 • ACR Convergence 2025
Differential Effects of GLP-1 Receptor Agonists versus SGLT2 Inhibitors on Hypoglycemia and Infection Risk in Diabetic Patients with Inflammatory Arthritis
Godbless Ajenaghughrure¹, Sila Mateo Faxas², Gurjot Singh³, Nirys Mateo Faxas⁴, Kim Nguyen³, Nicole Tejeda⁵ and Kimberly Ramirez Bonetti⁶, ¹Trihealth Good Samaritan Hospital, Cincinnati, OH, ²Good Samaritan Hospital, Cincinnati, OH, ³Trihealth Good Samaritan Hospital, Cincinnati, ⁴Independent Author, Santo Domingo, Dominican Republic, ⁵Independent Author, Cincinnati, ⁶Independent Author, cincinnati, OH
Background/Purpose: While both SGLT2 inhibitors and GLP-1 receptor agonists improve glycemic control in type 2 diabetes (T2D), their safety profiles, particularly regarding hypoglycemia and infection…
Abstract Number: 0066 • ACR Convergence 2025
RA-required synovial tissue-resident monocyte lineage cells are comprised of three distinct subpopulations.
Yidan Wang¹, Samuel Dowling², Jessica Maciuch², Vanessa Manada De Lobos², Meghan Mayer², Kainat Mian¹, Tyler Therron³, Hadijat Makinde¹, Carla Marie Cuda¹, Deborah Rachelle Winter⁴ and Harris R Perlman¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern Feinberg School of Medicine, Chicago, IL, ⁴Northwestern University, Skokie, IL
Background/Purpose: Tissue-resident monocyte-lineage cell (TRMC) are an extravascular population distinct from circulating monocytes and synovial macrophages and are critical for the development of inflammatory arthritis.…
Abstract Number: 2527 • ACR Convergence 2025
Safety Profile and Impaired Humoral Response to the Recombinant Herpes Zoster Vaccine in Behçet’s Syndrome Patients under Immunosuppression: a Prospective, Randomized, Placebo-Controlled Trial
Eduardo Borba¹, Caio Carvalho², Nadia E Aikawa³, Ana C Medeiros-Ribeiro², Sandra G Pasoto², Carla Saad⁴, Henrique Giardini⁵, Thiago Freitas⁵, Rafael Cordeiro⁶, Eloisa Bonfa¹ and Clovis Artur Silva⁷, ¹Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ³Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil, ⁷University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Although rare, new-onset Behçet’s syndrome (BS) and disease flares have been reported following vaccination. In this context, the recommendation of the Recombinant Herpes Zoster…
Abstract Number: 2085 • ACR Convergence 2025
Estimating the Association between Effusion-synovitis and Knee Pain in a Subset of Participants with Radiographic Knee Osteoarthritis: Data from the Osteoarthritis Initiative (OAI)
Dagoberto Robles¹, Greg Gilles², Nathaniel H. Christiansen³, Luke Grawer⁴, Karim Jayyusi⁴, Ali Shaikh⁴, Rongrong Tang⁵, Mihra S. Taljanovic⁴, Jeffrey Duryea⁶, Edward J. Bedrick⁵ and C. Kent Kwoh⁷, ¹University of Arizona, Tucson, AZ, ²University of Arizona Arthritis Center, The University of Arizona College of Medicine, Tucson, AZ, ³University of Arizona, Stockton, NJ, ⁴University of Arizona, Tucson, ⁵The University of Arizona Arthritis Center, University of Arizona, Tucson, ⁶Brigham and Women’s Hospital, Boston, MA, ⁷The University of Arizona Arthritis Center, University of Arizona, Tucson, AZ
Background/Purpose: Even though knee pain is ubiquitous in knee osteoarthritis (KOA) patients, currently there are limited treatment options which are only minimally or moderately efficacious…
Abstract Number: 1785 • ACR Convergence 2025
Soluble CD14 Amplifies Chondrocyte Inflammatory Responses to Lipopolysaccharide and Is Targetable by Anti-CD14 Therapy
Anna Rapp¹, Kate Sharp¹, Baofeng Hu² and Carla Scanzello¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Wynnewood, PA
Background/Purpose: Osteoarthritis (OA) is characterized by a pro-inflammatory joint microenvironment, including elevated levels of endogenous pattern recognition receptor ligands in synovial fluid. Notably, both lipopolysaccharide…
Abstract Number: 1458 • ACR Convergence 2025
Clinical Efficacy of Bimekizumab Treatment up to 2 Years Across Patients with Psoriatic Arthritis and Varying Baseline Joint Involvement: Results from a Post Hoc Analysis of Two Pooled Phase 3 Studies
Philip J. Mease¹, Laure Gossec², Hideto Kameda³, David Nicholls⁴, Proton Rahman⁵, Barbara Ink⁶, Rajan Bajracharya⁶, Patrick Healy⁷ and Laura Coates⁸, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ³Department of Internal Medicine, Toho University, Tokyo, Japan, ⁴Clinical Trials Unit, University of the Sunshine Coast, Queensland, Australia, ⁵Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ⁶UCB, Slough, England, United Kingdom, ⁷UCB, Morrisville, NC, ⁸Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Patients (pts) in PsA clinical trials often have greater joint involvement than in the clinical setting due to trial inclusion criteria,1 thus it is…
Abstract Number: 1119 • ACR Convergence 2025
Microbial activation of cytotoxic CD8⁺ T cells promotes skin immune-related adverse events in patients treated with immune checkpoint inhibitors
Shady Younis¹, Suman Acharya¹, Gayathri Swaminathan¹, Heidi Wong¹, Hannah Kim¹, Alec Eschholz¹, Subramanya Hegde², Andrew McKnight³, William Robinson⁴ and Lisa Zaba¹, ¹Stanford University, Stanford, CA, ²Sanofi US, New Jersey, MA, ³Sanofi US, Cambridge, MA, ⁴Stanford University, Palo Alto, CA
Background/Purpose: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their use is often limited by immune-related adverse events (irAEs), particularly in barrier tissues such…
Abstract Number: 0918 • ACR Convergence 2025
Retention of variant forms of TNFR1 in the Golgi induces stress responses and monocyte activation in systemic Juvenile Idiopathic Arthritis (sJIA)
Anthony Cruz¹, Krisztian Csomos¹, Boglarka Ujhazi¹, Hiroto Nakano², Marissa Krantz³, Sophia Chou⁴, Emily Rosenbaum¹, Tianmin Fu⁵, Dirk Foell⁶, Rae Yeung⁷, Pamela Weiss⁸, Faiza Naz⁹, Ly-Lan Bergeron¹, Michelle Millwood¹⁰, Carol Lake¹¹, Emely Verweyen⁶, Grant Schulert¹², Stefania Dell'orso⁹, Hao Wu¹³, Zuoming Deng¹⁴, davide Randazzo¹⁵ and Michael Ombrello¹⁶, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³University of Rochester, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Rockville, MD, ⁵Ohio State University College of Medicine, Columbus, OH, ⁶University Hospital Muenster, Muenster, Germany, ⁷The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁸Childrens Hospital of Philadelphia, Philadelphia, PA, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ¹⁰National Institutes of Health (NIH), Bethesda, MD, ¹¹NIH, GAITHERSBURG, MD, ¹²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹³Harvard University, Cambridge, MA, ¹⁴Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁵Light Imaging Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, ¹⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is severe and poorly understood inflammatory condition. Tumor necrosis factor receptor 1 (TNFR1) is activated by TNF and is…
Abstract Number: 0472 • ACR Convergence 2025
Detrimental Effects of Umbilical Cord Blood-derived Mesenchymal Stem Cells Intra-articular Injections on Pannus Invasiveness
Sung Eun Kim¹, Hye Lim Kang¹, Min Jung Kim², Hyung-Sik Kim³ and Kichul Shin⁴, ¹Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, ²Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, South Korea, ³Department of Oral Biochemistry, Pusan National University School of Dentistry, Yangsan, Republic of Korea, ⁴Seoul National University, Seoul, South Korea
Background/Purpose: Studies have shown that mesenchymal stem cell (MSC) infusion ameliorates arthritis in animal models. However, the first-pass effect in the lung has directed attention…
Abstract Number: 0226 • ACR Convergence 2025
Integration of the 5Ms of Geriatrics in a Novel Geri-Rheumatology Clinic
Justin Levinson¹ and Christie Bartels², ¹University of Wisconsin- Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Geriatric integrative care models, such as the Perioperative Optimization of Senior Health (POSH) initiative, have shown improved outcomes (PMID: 29299599), yet there remains limited…
Abstract Number: 0063 • ACR Convergence 2025
Effect of alpha-ketoglutarate on Synovial Fibroblasts-Mediated Inflammation in Arthritis
Surabhi Gautam, Vinay Devulapalli, Akash Sathiyamurthi, Jayla Whittaker and Pallavi Bhattaram, Emory University, Atlanta, GA
Background/Purpose: Rheumatoid arthritis (RA) and related autoimmune joint disease patients exhibit cyclic episodes of resolution and exacerbation of joint inflammation, referred to as flares. Fibroblast-like…
Abstract Number: 2497 • ACR Convergence 2025
Unraveling the Complexity of Interferon Responses in Peripheral Blood Mononuclear Cells in Systemic Sclerosis at Single-Cell Resolution
Pietro Bearzi¹, Elena Pachera², Astrid Hofman³, Laura Much⁴, Lumeng Li¹, Kristina Bürki³, Cosimo Bruni⁵, Mike Becker⁶, Anna-Maria Hoffmann-Vold⁷, Roberto Giacomelli⁸ and Oliver Distler⁹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zürich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁵University of Zurich, Zurich, Switzerland, ⁶Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ⁷Oslo University Hospital, Oslo, Norway, ⁸i) Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Campus Biomedico; ii) Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome "Campus Bio-Medico", Rome, Italy, ⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Autoimmunity is a hallmark of SSc pathogenesis. Emerging evidence suggests that interferon (IFN) signaling plays a role in predicting SSc patients at risk of…
Abstract Number: 2070 • ACR Convergence 2025
Characterization of Hospitalization, Patient Demographics and Impact of Idiopathic Inflammatory Myopathies on Hospitalization Outcomes in Adult Fracture Patients: A National Inpatient Sample Analysis.
Pranathi Bandarupalli¹, Vineeth Potluri², Amr Alemairy², Harsharn Grewal² and Shudipan Chakraborthy², ¹Mercy St Vincent Medical Center, Toledo, OH, ²Mercy Health St. Vincent Medical Center, Toledo, OH
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM), including polymyositis and dermatomyositis, are rare systemic autoimmune disorders characterized by chronic muscle inflammation and progressive muscle weakness. Patients with…
Abstract Number: 1776 • ACR Convergence 2025
Preclinical Development of a Novel TL1A-Targeting Antibody with Extended Half-life and Low Immunogenicity Risk for the Treatment of Inflammatory Diseases
Yali Zhou¹, Huilin Li¹, Hang Su¹, Mingjun Zhao¹, Haiying Wang¹, Qiong Wang¹, Xiaojin Zhang², Yanliu Fan¹, Lulu Li¹, Miaomiao Wang¹, Jinglu Xia¹, Wenyue Zong¹, Jingjing Li¹, Simin Yi¹, Bing Zou¹, Zhen Lu¹, Yali Wang¹, Yupeng Zhu¹, Lingjian Yang¹, Zenglin Pei¹, Barry Duplantis³, Yuhao Wang³, Yi Li¹ and Quan Yu¹, ¹Ailux, Shanghai, China (People's Republic), ²XtalPi, Shanghai, China (People's Republic), ³Ailux, Boston, MA
Background/Purpose: Autoimmune and inflammatory diseases such as inflammatory bowel disease (IBD) and psoriasis are driven by dysregulated cytokine networks. TL1A, a member of the TNF…

« Previous Page
1
…
4
5
6
7
8
…
67
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].